TriangleNCT00176930 · OUTCOME
Number of Participants Who Were Alive at 5 Year Post Transplant
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 5 years
What was measured
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
Groups in this outcome
PBSC: No TBI
Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
Marrow : No TBI
Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
UCB : No TBI
Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
UCB : No TBI/Bu/Cy/ATG
Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
PBSC
Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
Marrow
Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
Umbilical Cord Blood
Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
Co-Enroll From MT0403
Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)
| Group | Source count |
|---|---|
| PBSC: No TBI | 12 |
| Marrow : No TBI | 13 |
| UCB : No TBI | 1 |
| UCB : No TBI/Bu/Cy/ATG | 1 |
| PBSC | 213 |
| Marrow | 85 |
| Umbilical Cord Blood | 2 |
| Co-Enroll From MT0403 | 2 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PBSC: No TBI | 3 | Not reported | Not reported | Not reported | Not reported |
| Marrow : No TBI | 9 | Not reported | Not reported | Not reported | Not reported |
| UCB : No TBI | 0 | Not reported | Not reported | Not reported | Not reported |
| UCB : No TBI/Bu/Cy/ATG | 0 | Not reported | Not reported | Not reported | Not reported |
| PBSC | 100 | Not reported | Not reported | Not reported | Not reported |
| Marrow | 54 | Not reported | Not reported | Not reported | Not reported |
| Umbilical Cord Blood | 2 | Not reported | Not reported | Not reported | Not reported |
| Co-Enroll From MT0403 | 2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 100
- group Id
- OG005
- value
- 54
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 2
- denoms
- counts
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 13
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 213
- group Id
- OG005
- value
- 85
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 2
- units
- Participants
- description
- The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
- groups
- description
- Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
- id
- OG000
- title
- PBSC: No TBI
- description
- Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
- id
- OG001
- title
- Marrow : No TBI
- description
- Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
- id
- OG002
- title
- UCB : No TBI
- description
- Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
- id
- OG003
- title
- UCB : No TBI/Bu/Cy/ATG
- description
- Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
- id
- OG004
- title
- PBSC
- description
- Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
- id
- OG005
- title
- Marrow
- description
- Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
- id
- OG006
- title
- Umbilical Cord Blood
- description
- Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)
- id
- OG007
- title
- Co-Enroll From MT0403
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- 5 years
- title
- Number of Participants Who Were Alive at 5 Year Post Transplant
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice